Our investment approach...
We invest by partnering with life science companies in all stages of clinical development (Phase I-IV clinical trial), and we believe that our risk-sharing business practices are suited to the current market challenges.
We are flexible on the scope and stage of the development program, as well as the nature of our return on investment. Technomark only invests in projects in which we feel that we can make a difference in development or regulatory strategy by leveraging our internal expertise and global reach. We not only co-invest with other institutional investors, but also just with the life science company as part of a co-development agreement. |
|
|
Investment Summary |
Industry sector: |
|
Therapeutics (biologics, NCE, orphan), med-tech, device/diagnostic |
Size of investment: |
|
Seed Funding to Series C |
Investment stage: |
|
Phase I-IV clinical trial |
Return on investment: |
|
Equity, downstream royalties, milestone payments, etc. |
Geography: |
|
UK and rest of EU, US, Israel, etc. |
|